Waters Corporation
NYSE•WAT
執行長: Dr. Udit Batra Ph.D.
板塊: Healthcare
行業: Medical - Diagnostics & Research
上市日期: 1995-11-17
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.
聯絡資訊
市值
$18.78B
本益比 (TTM)
29.2
31.5
股息率
--
52周最高
$414.15
52周最低
$275.05
52周範圍
排名27Top 14.4%
5.4
F-Score
改良版 Piotroski 分析
基於 10 年期基本面
一般 • 5.4 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2016-2025
財務儀表板
Q4 2025 數據
營業收入
$932.36M+0.00%
近4季度走勢
每股收益
$3.78+0.00%
近4季度走勢
自由現金流
$125.58M+0.00%
近4季度走勢
2025 Annual 財報亮點
核心亮點
Total Net Sales Increase Total net sales reached $3.17B USD in 2025, marking a 7% increase driven by strong customer demand across major geographies.
Chemistry Consumables Growth Chemistry consumables sales grew 12% to $631.5M USD in 2025, supported by uptake in columns and pharmaceutical testing kits.
Transformative BDS Acquisition Completed $16.8B USD acquisition of BD Biosciences & Diagnostic Solutions in February 2026, establishing a global life sciences leader.
Net Income Remained Stable Net income was $642.6M USD in 2025, showing a 1% increase despite operating income declining 3% from prior year.
關注風險
BDS Integration Challenges Failure to integrate BDS Business within expected timeline could adversely affect future results and realization of anticipated synergies.
Foreign Currency Fluctuation Risk International operations face negative impact from foreign currency fluctuations, affecting translation of non-U.S. operating results.
Customer Demand Changes Financial results subject to changes in customer demand, especially pharmaceutical spending, which may decrease beyond Company control.
Competitive Technology Disruption Competitors may introduce more effective or less expensive products, potentially decreasing sales and harming market position.
未來展望
Increased R&D Investment R&D expenses increased 7% in 2025 to $195.7M USD, reflecting commitment to new product development and technology initiatives.
New Four Segment Structure Reorganized business into four segments post-BDS acquisition: Analytical, Biosciences, Advanced Diagnostics, and Materials Sciences.
Realizing Acquisition Synergies Expect cost synergies of $200M USD within three years and revenue synergies of $290M USD within five years post-BDS close.
Share Repurchase Authorization Board authorized share repurchase extension through January 2028, maintaining $1.0B remaining authorization capacity.
同行對比
營業收入 (TTM)
$13.95B
$11.04B
$9.81B
毛利率 (最新季度)
92.3%
90.9%
86.9%
關鍵指標
股票代碼 | 市值 | 本益比 (TTM) | 股東權益報酬率 (TTM) | 負債率 |
|---|---|---|---|---|
| BIIB | $27.60B | 21.3 | 7.3% | 23.6% |
| DXCM | $27.57B | 32.7 | 32.4% | 21.9% |
| MTD | $25.76B | 29.6 | -487.2% | 63.1% |
長期趨勢
近4季度
營業收入
淨利
營運現金流
4季度營業收入複合增長率
12.1%
穩定增長
4季度淨利複合增長率
22.9%
盈利能力大幅提升
現金流穩定性
100%
現金流表現優異
深度研究
下次財報:2026年5月4日
每股收益:-
|營業收入:-
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表 | 過去12個月 |
|---|
無資料